JP2017521101A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017521101A5 JP2017521101A5 JP2017522459A JP2017522459A JP2017521101A5 JP 2017521101 A5 JP2017521101 A5 JP 2017521101A5 JP 2017522459 A JP2017522459 A JP 2017522459A JP 2017522459 A JP2017522459 A JP 2017522459A JP 2017521101 A5 JP2017521101 A5 JP 2017521101A5
- Authority
- JP
- Japan
- Prior art keywords
- primary
- lymphocytes
- contacting
- lymphocyte
- vector
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 36
- 102000007327 Protamines Human genes 0.000 claims description 3
- 108010007568 Protamines Proteins 0.000 claims description 3
- 239000003153 chemical reaction reagent Substances 0.000 claims description 3
- 229950008679 protamine sulfate Drugs 0.000 claims description 3
- 230000009466 transformation Effects 0.000 claims description 3
- 238000000034 method Methods 0.000 claims 17
- 230000001177 retroviral effect Effects 0.000 claims 16
- 150000007523 nucleic acids Chemical class 0.000 claims 9
- 102000039446 nucleic acids Human genes 0.000 claims 9
- 108020004707 nucleic acids Proteins 0.000 claims 9
- MWBWWFOAEOYUST-UHFFFAOYSA-N 2-aminopurine Chemical compound NC1=NC=C2N=CNC2=N1 MWBWWFOAEOYUST-UHFFFAOYSA-N 0.000 claims 8
- 102000000588 Interleukin-2 Human genes 0.000 claims 6
- 108010002350 Interleukin-2 Proteins 0.000 claims 6
- 150000001875 compounds Chemical class 0.000 claims 5
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 3
- 229920002491 Diethylaminoethyl-dextran Polymers 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 102000004127 Cytokines Human genes 0.000 claims 2
- 108090000695 Cytokines Proteins 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 1
- 108091008874 T cell receptors Proteins 0.000 claims 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 210000005007 innate immune system Anatomy 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 229920002307 Dextran Polymers 0.000 description 2
- 229960000633 dextran sulfate Drugs 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 241000713666 Lentivirus Species 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462023618P | 2014-07-11 | 2014-07-11 | |
| US62/023,618 | 2014-07-11 | ||
| PCT/US2015/039892 WO2016007827A1 (en) | 2014-07-11 | 2015-07-10 | Methods of improving vector transduction efficiency into t lymphocytes |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020141042A Division JP2020191901A (ja) | 2014-07-11 | 2020-08-24 | Ｔリンパ球へのベクター導入効率の改善方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017521101A JP2017521101A (ja) | 2017-08-03 |
| JP2017521101A5 true JP2017521101A5 (cg-RX-API-DMAC7.html) | 2018-08-30 |
| JP6754761B2 JP6754761B2 (ja) | 2020-09-16 |
Family
ID=55064944
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017522459A Active JP6754761B2 (ja) | 2014-07-11 | 2015-07-10 | Ｔリンパ球へのベクター導入効率の改善方法 |
| JP2020141042A Pending JP2020191901A (ja) | 2014-07-11 | 2020-08-24 | Ｔリンパ球へのベクター導入効率の改善方法 |
| JP2023000651A Pending JP2023040152A (ja) | 2014-07-11 | 2023-01-05 | Ｔリンパ球へのベクター導入効率の改善方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020141042A Pending JP2020191901A (ja) | 2014-07-11 | 2020-08-24 | Ｔリンパ球へのベクター導入効率の改善方法 |
| JP2023000651A Pending JP2023040152A (ja) | 2014-07-11 | 2023-01-05 | Ｔリンパ球へのベクター導入効率の改善方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US10982189B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3167058B1 (cg-RX-API-DMAC7.html) |
| JP (3) | JP6754761B2 (cg-RX-API-DMAC7.html) |
| ES (2) | ES2813437T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2016007827A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11493428B2 (en) | 2013-03-15 | 2022-11-08 | Gpb Scientific, Inc. | On-chip microfluidic processing of particles |
| US20150064153A1 (en) | 2013-03-15 | 2015-03-05 | The Trustees Of Princeton University | High efficiency microfluidic purification of stem cells to improve transplants |
| EP2971279B1 (en) | 2013-03-15 | 2019-11-13 | The Trustees of Princeton University | Methods and devices for high throughput purification |
| JP6754761B2 (ja) * | 2014-07-11 | 2020-09-16 | セルジーン コーポレイション | Ｔリンパ球へのベクター導入効率の改善方法 |
| US10976232B2 (en) | 2015-08-24 | 2021-04-13 | Gpb Scientific, Inc. | Methods and devices for multi-step cell purification and concentration |
| US10844353B2 (en) | 2017-09-01 | 2020-11-24 | Gpb Scientific, Inc. | Methods for preparing therapeutically active cells using microfluidics |
| DE102018010282A1 (de) | 2018-01-17 | 2019-07-18 | Immatics US, Inc. | Verfahren zur Feststellung der Wirksamkeit von viralen Vektoren |
| DE102018100967B4 (de) | 2018-01-17 | 2019-08-14 | Immatics US, Inc. | Verfahren zur feststellung der wirksamkeit von viralen vektoren |
| CN108715865B (zh) * | 2018-05-28 | 2021-09-21 | 福建师范大学 | 用于提高细胞转染效率的试剂组合物 |
| EP3999081A1 (en) | 2019-07-18 | 2022-05-25 | GPB Scientific, Inc. | Ordered processing of blood products to produce therapeutically active cells |
| JP2023508465A (ja) | 2019-12-28 | 2023-03-02 | ジーピービー・サイエンティフィック・インコーポレイテッド | 粒子および細胞を処理するためのマイクロ流体カートリッジ |
| KR20230167384A (ko) * | 2021-04-06 | 2023-12-08 | 유니세트 바이오테크 씨오. 엘엘씨 | γδ T 세포의 바이러스 형질 도입의 안정성을 개선하기 위한 방법 및 이의 응용 |
| WO2023286088A1 (en) * | 2021-07-16 | 2023-01-19 | Indian Institute Of Science Education And Research Bhopal | Methods and compositions for viral vector transduction |
| WO2025180499A1 (zh) * | 2024-02-28 | 2025-09-04 | 南京因领生物科技有限公司 | 一种提高细胞中病毒包装产量或质量的方法 |
| CN119530302B (zh) * | 2025-01-22 | 2025-06-27 | 青岛华赛伯曼医学细胞生物有限公司 | 提高til细胞的慢病毒转导效率及转导稳定性的方法及试剂盒 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
| US5665577A (en) | 1989-02-06 | 1997-09-09 | Dana-Farber Cancer Institute | Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof |
| IL104570A0 (en) | 1992-03-18 | 1993-05-13 | Yeda Res & Dev | Chimeric genes and cells transformed therewith |
| US8211422B2 (en) | 1992-03-18 | 2012-07-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric receptor genes and cells transformed therewith |
| US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
| EP0824594B1 (en) * | 1995-05-04 | 2005-04-06 | The United States of America as Representend by The Secretary of the Navy | Improved methods for transfecting t cells |
| US5948893A (en) | 1996-01-17 | 1999-09-07 | The United States Of America As Represented By The Secretary Of The Navy | Murine hybridoma and antibody binding to CD28 receptor secreted by the hybridoma and method of using the antibody |
| US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
| ATE528406T1 (de) | 1999-04-29 | 2011-10-15 | Gbp Ip Llc | Verfahren und mittel zur herstellung von sicheren,rekombinanten lentivirusvektoren mit hohem titer |
| EP2336299A1 (en) | 2001-02-14 | 2011-06-22 | Anthrogenesis Corporation | Post-partum mammalian placenta, its use and placental stem cells therefrom |
| US20060210536A1 (en) * | 2003-04-17 | 2006-09-21 | Curt Horvath | Methods and compositions for inhibiting stat signaling pathways |
| ATE488252T1 (de) * | 2003-05-05 | 2010-12-15 | Virxsys Corp | Erhöhte transduktion mit abc- transportersubstratenhemmern |
| US20080311095A1 (en) * | 2007-05-23 | 2008-12-18 | Sangamo Biosciences, Inc. | Methods and compositions for increased transgene expression |
| WO2006089001A2 (en) * | 2005-02-16 | 2006-08-24 | Lentigen Corporation | Lentiviral vectors and their use |
| GB0526255D0 (en) | 2005-12-22 | 2006-02-01 | Novartis Ag | Organic compounds |
| PT2471907T (pt) | 2005-12-29 | 2019-01-28 | Celularity Inc | Populações de células estaminais placentárias |
| AU2008307633C1 (en) | 2007-09-28 | 2015-04-30 | Celularity Inc. | Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells |
| JP5869342B2 (ja) | 2008-11-19 | 2016-02-24 | アンスロジェネシス コーポレーション | 羊膜由来接着細胞 |
| EP3358007A1 (en) | 2010-07-13 | 2018-08-08 | Celularity, Inc. | Methods of generating natural killer cells |
| WO2012072096A1 (en) * | 2010-12-03 | 2012-06-07 | Biontech Ag | Method for cellular rna expression |
| DK3763820T3 (da) * | 2012-02-29 | 2022-02-07 | Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Gesundheit & Umwelt Gmbh | Retroviral transduktion ved hjælp af poloxamerer |
| EP2836239A1 (en) * | 2012-04-11 | 2015-02-18 | The United States of America, as Represented By the Secretary, Department of Health and Human Services | Chimeric antigen receptors targeting b-cell maturation antigen |
| WO2014046617A1 (en) * | 2012-09-19 | 2014-03-27 | Agency For Science, Technology And Research | Compositions and methods for treating cancer |
| JP6754761B2 (ja) * | 2014-07-11 | 2020-09-16 | セルジーン コーポレイション | Ｔリンパ球へのベクター導入効率の改善方法 |
-
2015
- 2015-07-10 JP JP2017522459A patent/JP6754761B2/ja active Active
- 2015-07-10 US US15/325,376 patent/US10982189B2/en active Active
- 2015-07-10 WO PCT/US2015/039892 patent/WO2016007827A1/en not_active Ceased
- 2015-07-10 EP EP15818898.7A patent/EP3167058B1/en active Active
- 2015-07-10 EP EP20176483.4A patent/EP3750993B1/en active Active
- 2015-07-10 ES ES15818898T patent/ES2813437T3/es active Active
- 2015-07-10 ES ES20176483T patent/ES2973524T3/es active Active
-
2020
- 2020-08-24 JP JP2020141042A patent/JP2020191901A/ja active Pending
-
2021
- 2021-03-12 US US17/200,745 patent/US11629335B2/en active Active
-
2023
- 2023-01-05 JP JP2023000651A patent/JP2023040152A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017521101A5 (cg-RX-API-DMAC7.html) | ||
| JP2020191901A5 (cg-RX-API-DMAC7.html) | ||
| PE20210256A1 (es) | Anticuerpos anti-lag3 | |
| JP2012143232A5 (cg-RX-API-DMAC7.html) | ||
| AR095980A1 (es) | Anticuerpos biespecíficos específicos para fap (proteína de activación fibroblástica) y dr5 (receptor de muerte 5), anticuerpos específicos para dr5 y métodos de utilización | |
| EA201590184A1 (ru) | Вакцина на основе микобактериальных антигенов | |
| NZ610267A (en) | A monoclonal antibody framework binding interface for meditopes, meditope delivery systems and methods for their use | |
| MX2018001739A (es) | Receptores de antígenos quiméricos basados en anticuerpos de dominio simple y métodos de uso de estos. | |
| AR095432A1 (es) | Proteínas de unión a antígeno | |
| JP2015227386A5 (cg-RX-API-DMAC7.html) | ||
| WO2017079479A8 (en) | Neutralizing antibodies to hiv-1 gp41 and their use | |
| WO2016196975A8 (en) | Neutralizing antibodies to hiv-1 env and their use | |
| PE20180480A1 (es) | Anticuerpos de factor xi y metodos de uso | |
| JP2019523221A5 (cg-RX-API-DMAC7.html) | ||
| EA201891410A1 (ru) | Антитела к с5 и способы их применения | |
| WO2019165122A8 (en) | Neutralizing antibodies to hiv-1 env and their use | |
| EA202091569A1 (ru) | Моноклональные антитела и способы их применения | |
| PH12022551580A1 (en) | Anti-ctla-4 antibody and use thereof | |
| NI201800113A (es) | Anticuerpos anti-basigin humanizados y uso de los mismos. | |
| Ionov et al. | An immunoproteomic survey of the antibody landscape: insights and opportunities revealed by serological repertoire profiling | |
| Li et al. | Affinity-independent memory B cell origin of the early antibody-secreting cell response in naive individuals upon SARS-CoV-2 vaccination | |
| JP2019513346A5 (cg-RX-API-DMAC7.html) | ||
| EP3495386A1 (en) | Specific monoclonal antibodies of the antigen m of the human metapneumovirus (hmpv) and use thereof in a diagnostic method | |
| MX2023007583A (es) | Metodos para obtener anticuerpos que se unen a proteinas transmembranarias y celulas que los producen. | |
| Silva de Castro et al. | Expression of CD40L by the ALVAC-simian immunodeficiency virus vector abrogates T cell responses in macaques |